Abuse-liability data on Intelli's opioid drug missing: FDA staff

(Reuters) - U.S. Food and Drug Administration scientists on Monday raised concerns that Intellipharmaceutics International Inc failed to provide data from studies testing the abuse potential of its long-acting opioid painkiller.